The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection):a randomised placebo-controlled trial

Autoria(s): Baigent, Colin; Landray, Martin J; Reith, Christina; Emberson, Jonathan; Wheeler, David C; Tomson, Charles; Wanner, Christoph; Krane, Vera; Cass, Alan; Craig, Jonathan; Neal, Bruce; Jiang, Lixin; Hooi, Lai Seong; Levin, Adeera; Agodoa, Lawrence; Gaziano, Mike; Kasiske, Bertram; Walker, Robert; Massy, Ziad A; Feldt-Rasmussen, Bo; Krairittichai, Udom; Ophascharoensuk, Vuddidhej; Fellström, Bengt; Holdaas, Hallvard; Tesar, Vladimir; Wiecek, Andrzej; Grobbee, Diederick; de Zeeuw, Dick; Grönhagen-Riska, Carola; Dasgupta, Tanaji; Lewis, David; Herrington, William; Mafham, Marion; Majoni, William; Wallendszus, Karl; Grimm, Richard; Pedersen, Terje; Tobert, Jonathan; Armitage, Jane; Baxter, Alex; Bray, Christopher; Chen, Yiping; Chen, Zhengming; Hill, Michael; Knott, Carol; Parish, Sarah; Simpson, David; Sleight, Peter; Young, Alan; Collins, Rory; SHARP Investigators; Maxwell, Alexander
Data(s)

25/06/2011
Resumo

Lowering LDL cholesterol with statin regimens reduces the risk of myocardial infarction, ischaemic stroke, and the need for coronary revascularisation in people without kidney disease, but its effects in people with moderate-to-severe kidney disease are uncertain. The SHARP trial aimed to assess the efficacy and safety of the combination of simvastatin plus ezetimibe in such patients.
Identificador

http://pure.qub.ac.uk/portal/en/publications/the-effects-of-lowering-ldl-cholesterol-with-simvastatin-plus-ezetimibe-in-patients-with-chronic-kidney-disease-study-of-heart-and-renal-protection(6dfb1c27-aeba-490e-b12c-8b2e0cc425bf).html

http://dx.doi.org/10.1016/S0140-6736(11)60739-3
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

Baigent , C , Landray , M J , Reith , C , Emberson , J , Wheeler , D C , Tomson , C , Wanner , C , Krane , V , Cass , A , Craig , J , Neal , B , Jiang , L , Hooi , L S , Levin , A , Agodoa , L , Gaziano , M , Kasiske , B , Walker , R , Massy , Z A , Feldt-Rasmussen , B , Krairittichai , U , Ophascharoensuk , V , Fellström , B , Holdaas , H , Tesar , V , Wiecek , A , Grobbee , D , de Zeeuw , D , Grönhagen-Riska , C , Dasgupta , T , Lewis , D , Herrington , W , Mafham , M , Majoni , W , Wallendszus , K , Grimm , R , Pedersen , T , Tobert , J , Armitage , J , Baxter , A , Bray , C , Chen , Y , Chen , Z , Hill , M , Knott , C , Parish , S , Simpson , D , Sleight , P , Young , A , Collins , R , SHARP Investigators & Maxwell , A 2011 , ' The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection) : a randomised placebo-controlled trial ' Lancet , vol 377 , no. 9784 , pp. 2181-92 . DOI: 10.1016/S0140-6736(11)60739-3
Palavras-Chave #/dk/atira/pure/subjectarea/asjc/2700 #Medicine(all)
Tipo

article
Acesso ao item digital